Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Journey Medical CorporationNASDAQ: DERM

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $10.11M fell 4.7% year over year, behind the +5.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Operating expenses amounted to 72.5% of revenue in FY2025, down 14.7 pp from a year earlier.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -4.7% toward the trailing-twelve-month pace of +5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.11M+0.9% QoQ
Last fiscal yearDec 2025
$44.85M-8.3% YoY
LTMMar 2026
$45.41M+5.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.7%——
1 year-8.3%——
3-year CAGR-14.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
44.85M USD
Year-over-year change
-8.3%
4-year CAGR
-9.2%

Operating Expenses vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.0% is the 9th highest of 10, against a peer median of +30.6%.
  • Operating expenses amounts to 70.2% of revenue for DERM, versus a peer median of 267.2%.
DERM Competitors
Operating Expenses for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€137.37M EUR+28.7%+22.8%3064.2%
OSUROraSure Technologies, Inc.LTM Mar 2026$119.39M USD+14.5%-8.9%105.6%
OGIOrganigram Global Inc.LTM Mar 2026CA$111.83M CAD+35.4%—40.8%
NYXHNyxoah S.A.LTM Mar 2026€93.92M EUR+34.0%+37.4%575.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$87.45M USD+22.4%+33.4%267.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$80.29M USD-7.3%-1.7%4523.5%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$52.67M USD+31.8%+25.0%103.3%
DERMJourney Medical CorporationLTM Mar 2026$45.41M USD+5.0%-14.0%70.2%
MDWDMediWound Ltd.LTM Mar 2026$30.87M USD+30.6%+11.1%213.2%
HSDTSolana CompanyLTM Mar 2026$27.89M USD+94.3%+18.9%290.8%
Peer median (excluding DERM) —+30.6%+20.9%267.2%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.